Advances in the Treatment of Psoriasis and Other Autoimmune Disorders

Lisa B. Samalonis, Managing Editor, The Dermatologist

 

The Dermatologist spoke with Joel M. Gelfand, MD, MSCE, associate professor of dermatology and epidemiology, Perelman School of Medicine, University of Pennsylvania in Philadelphia, Pennsylvania, about his involvement with The 2018 Interdisciplinary Autoimmune Summit (IAS) meeting, the evolving landscape of psoriasis, and his outlook on the future of immune-mediated inflammatory diseases (IMIDs).

Harvard Medical School

Harvard Medical School

Harvard Medical School/

Brigham and Women’s Hospital

Introducing the launch of IAS360.com.

The network was created to fill an unmet need in the auto-immune space, providing specialists with a year-round resource of news, information, and education to help you treat patients with immune-mediated inflammatory diseases (IMIDs), including:

MALVERN, PA (Tuesday, March 7, 2017) — The IAS, the nation’s leading autoimmune conference and exhibition, today announced that it has received endorsement from the AGA Institute, the organization that runs the American Gastroenterological Association’s practice, research, and educational programs. IAS is owned and produced by HMP Communications Holdings, LLC, a recognized leader in healthcare content and continuing medical education events.

Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology, University of Pennsylvania Perelman School of Medicine, has researched and published extensively on the epidemiology of psoriasis and psoriatic arthritis, the impact of psoriasis on health-related quality of life, and the risk of various comorbidities such as obesity, diabetes, hyperlipidemia, lymphoma, renal disease, dementia, major cardiovascular events, and mortality associated with psoriasis. Dr.

Scientists believe that certain synovial cells contribute to inflammation by activating synovial fibroblasts in people who suffer from rheumatoid arthritis (RA). They believe that having a deeper understanding of the mechanisms of inflammation in the disease is important for designing new therapies for RA.

Patients with inflammatory bowel disease are more likely to see dramatic shifts in the make-up of the community of microbes in their gut than healthy people, according to the results of a study published online Feb. 13 in Nature Microbiology.

The prevalence of diabetes is higher in patients with psoriatic arthritis (PsA), with greater PsA activity correlating with a higher risk of developing the disease, according to recent research published in The Journal of Rheumatology.


Pages